KCNN2

Small conductance calcium-activated potassium channel protein 2 · Q9H2S1 · KCNN2 on Sugi Atlas →

5,148 patent compounds predicted against KCNN2, 3,381 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3250242	1.00	4/20
Hydrochloric Acid (SCHEMBL3254146)	1.00	4/20
Hydrochloric Acid (SCHEMBL3248635)	0.94	4/20
SCHEMBL3253219	0.94	4/20
Hydrochloric Acid (SCHEMBL3250094)	0.92	4/20
SCHEMBL3251892	0.91	4/20
Methopholine (SCHEMBL26169)	0.67	4/20
SCHEMBL2112478	0.67	4/20
Hydrochloric Acid (SCHEMBL3248244)	0.65	4/20
SCHEMBL3250383	0.64	4/20
SCHEMBL1760713	0.63	4/20
Hydrochloric Acid (SCHEMBL3253192)	0.61	4/20
SCHEMBL3244548	0.60	4/20
SCHEMBL4412560	0.58	4/20
SCHEMBL4415052	0.58	4/20
Hydrochloric Acid (SCHEMBL3263954)	0.56	4/20
SCHEMBL3245156	0.55	4/20
Hydrochloric Acid (SCHEMBL3254136)	0.52	4/20
Hydrochloric Acid (SCHEMBL3253137)	0.51	4/20
SCHEMBL3255532	0.51	4/20

Clinical trials — most relevant to KCNN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Targeted Potassium Levels for Prevention of ICD Therapy	PHASE4	ACTIVE_NOT_RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Diuretics, Hypertension, and Arrhythmias Clinical Trial	PHASE3	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF	nan	COMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Impact of Persistent Conductances on Motor Unit Firing in SCI	nan	UNKNOWN
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNN2 binder may also engage these)

Protein	Name	Similarity
P70604	—	1.000	P70604 →
KCNN3	Small conductance calcium-activated potassium channel protein 3	0.998	landscape →
P58392	—	0.995	P58392 →
P70605	—	0.989	P70605 →
P58391	—	0.989	P58391 →
P58390	—	0.984	P58390 →
Q02280	—	0.982	Q02280 →
HCN1	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	0.981	landscape →
Q9VGH7	—	0.980	Q9VGH7 →
G5EGS5	—	0.979	G5EGS5 →
P19334	—	0.979	P19334 →
P16388	—	0.979	P16388 →
Q7KVW5	—	0.979	Q7KVW5 →
Q2UKE6	—	0.979	Q2UKE6 →
P63141	—	0.979	P63141 →
Q9JIS8	—	0.979	Q9JIS8 →
P63142	—	0.979	P63142 →
Q29BL9	—	0.979	Q29BL9 →
Q9UHW9	—	0.978	Q9UHW9 →
P91682	—	0.978	P91682 →
Q9TTT5	—	0.978	Q9TTT5 →
Q64398	—	0.978	Q64398 →
Q28204	—	0.978	Q28204 →
Q9VR59	—	0.978	Q9VR59 →
J9VF17	—	0.978	J9VF17 →
KCNN1	Small conductance calcium-activated potassium channel protein 1	0.978	landscape →
Q03720	—	0.977	Q03720 →
O88704	—	0.977	O88704 →
P48994	—	0.977	P48994 →
Q2TV84	—	0.977	Q2TV84 →